Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:AORTNASDAQ:ESTANASDAQ:EYENASDAQ:SMTI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAORTArtivion$31.17+1.8%$27.99$21.97▼$32.33$1.33B1.62336,700 shs543,052 shsESTAEstablishment Labs$40.93+0.2%$35.37$26.56▼$52.41$1.18B0.74474,233 shs471,003 shsEYENational Vision$23.17+0.5%$18.48$9.56▼$23.42$1.83B1.241.92 million shs1.99 million shsSMTISanara MedTech$28.41+0.2%$30.23$25.86▼$39.08$252.51M1.3527,739 shs104,676 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAORTArtivion0.00%+2.87%+4.63%+28.50%+28.06%ESTAEstablishment Labs0.00%+8.25%+18.02%+1.24%-6.10%EYENational Vision0.00%+1.27%+16.14%+80.73%+84.03%SMTISanara MedTech0.00%+4.14%-3.07%-5.90%+1.43%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAORTArtivion2.6077 of 5 stars1.64.00.00.03.52.51.9ESTAEstablishment Labs2.3074 of 5 stars3.41.00.00.02.52.50.6EYENational Vision2.3735 of 5 stars2.22.00.03.31.60.80.0SMTISanara MedTech2.1979 of 5 stars3.51.00.00.02.71.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAORTArtivion 3.14Buy$32.002.67% UpsideESTAEstablishment Labs 2.80Moderate Buy$52.4028.02% UpsideEYENational Vision 2.44Hold$18.67-19.44% DownsideSMTISanara MedTech 3.00Buy$49.5074.23% UpsideCurrent Analyst Ratings BreakdownLatest SMTI, AORT, ESTA, and EYE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/18/2025EYENational VisionBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$22.00 ➝ $26.006/17/2025AORTArtivionCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$35.006/13/2025ESTAEstablishment LabsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$48.005/19/2025EYENational VisionBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetMarket Perform ➝ Market Perform$13.00 ➝ $19.005/16/2025ESTAEstablishment LabsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy ➝ Buy$62.005/15/2025SMTISanara MedTechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$51.00 ➝ $53.005/14/2025ESTAEstablishment LabsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$48.005/12/2025EYENational VisionBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$14.00 ➝ $17.005/9/2025EYENational VisionThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$13.00 ➝ $17.005/9/2025EYENational VisionCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$13.00 ➝ $21.005/8/2025EYENational VisionUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$18.00 ➝ $20.00(Data available from 6/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAORTArtivion$388.54M3.43$0.83 per share37.39$6.59 per share4.73ESTAEstablishment Labs$166.02M7.13N/AN/A$1.90 per share21.54EYENational Vision$1.82B1.00$1.64 per share14.16$10.37 per share2.23SMTISanara MedTech$86.67M2.91N/AN/A$4.45 per share6.38Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAORTArtivion-$13.36M-$0.50N/A62.34N/A-5.49%3.63%1.34%8/6/2025 (Estimated)ESTAEstablishment Labs-$84.60M-$3.10N/AN/AN/A-52.34%-196.25%-26.64%8/5/2025 (Estimated)EYENational Vision-$28.50M-$0.33N/A85.813.40-1.40%3.44%1.40%8/6/2025 (Estimated)SMTISanara MedTech-$9.66M-$1.34N/AN/AN/A-12.48%-29.22%-13.20%8/11/2025 (Estimated)Latest SMTI, AORT, ESTA, and EYE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025SMTISanara MedTech-$0.31-$0.41-$0.10-$0.41$23.48 million$23.43 million5/7/2025Q1 2025ESTAEstablishment Labs-$0.83-$0.70+$0.13-$0.70$41.15 million$41.38 million5/7/2025Q1 2025EYENational Vision$0.32$0.34+$0.02$0.18$510.30 million$510.32 million5/5/2025Q1 2025AORTArtivion$0.12$0.06-$0.06-$0.01$94.81 million$98.98 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAORTArtivionN/AN/AN/AN/AN/AESTAEstablishment LabsN/AN/AN/AN/AN/AEYENational VisionN/AN/AN/AN/AN/ASMTISanara MedTechN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAORTArtivion1.085.533.95ESTAEstablishment Labs5.723.362.05EYENational Vision0.290.540.35SMTISanara MedTech1.182.772.54Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAORTArtivion86.37%ESTAEstablishment Labs72.91%EYENational VisionN/ASMTISanara MedTech8.10%Insider OwnershipCompanyInsider OwnershipAORTArtivion7.60%ESTAEstablishment Labs11.09%EYENational Vision2.70%SMTISanara MedTech42.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAORTArtivion1,60042.70 million39.46 millionOptionableESTAEstablishment Labs1,01828.92 million25.71 millionOptionableEYENational Vision13,41179.05 million76.92 millionOptionableSMTISanara MedTech608.89 million5.10 millionNot OptionableSMTI, AORT, ESTA, and EYE HeadlinesRecent News About These CompaniesCantor Fitzgerald Estimates Sanara MedTech FY2026 EarningsJune 11, 2025 | marketbeat.comSanara MedTech: Pursuing Rapid Expansion While Debt Levels ClimbJune 9, 2025 | seekingalpha.comSanara MedTech Inc. (NASDAQ:SMTI) Short Interest Down 13.7% in MayJune 5, 2025 | marketbeat.comSanara MedTech Shares Down, Investors Sought For Pilot ProgramMay 15, 2025 | marketwatch.comEarnings call transcript: Sanara Medtech Q1 2025 earnings miss forecastsMay 15, 2025 | investing.comEarnings call transcript: Sanara Medtech Q1 2025 earnings miss forecastsMay 15, 2025 | investing.comSanara MedTech Inc (SMTI) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid Rising ...May 15, 2025 | finance.yahoo.comSanara MedTech Inc (SMTI) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid Rising ...May 15, 2025 | finance.yahoo.comSanara MedTech Inc. (NASDAQ:SMTI) Q1 2025 Earnings Call TranscriptMay 15, 2025 | msn.comSanara MedTech Inc. (NASDAQ:SMTI) Q1 2025 Earnings Call TranscriptMay 15, 2025 | msn.comSanara MedTech Inc. (SMTI) Q1 2025 Earnings Call TranscriptMay 14, 2025 | seekingalpha.comSanara MedTech Inc. (SMTI) Reports Q1 Loss, Tops Revenue EstimatesMay 14, 2025 | zacks.comSanara MedTech Inc. Reports First Quarter 2025 Financial Results (Unaudited)May 14, 2025 | gurufocus.comSanara MedTech Inc. Reports First Quarter 2025 Financial Results (Unaudited) | SMTI Stock NewsMay 14, 2025 | gurufocus.comSanara MedTech Inc. Reports First Quarter 2025 Financial Results (Unaudited)May 14, 2025 | investing.comSanara MedTech Inc. Reports First Quarter 2025 Financial Results (Unaudited)May 14, 2025 | globenewswire.comWith 31% ownership, Sanara MedTech Inc. (NASDAQ:SMTI) insiders have a lot riding on the company's futureMay 6, 2025 | uk.finance.yahoo.comSanara MedTech Inc. to Report Q1 2025 Financial Results on May 14, 2025April 23, 2025 | quiverquant.comQSanara MedTech to Report First Quarter 2025 Financial Results on May 14, 2025April 23, 2025 | globenewswire.comSanara MedTech to Present at Investor ShowcaseApril 22, 2025 | tipranks.comSanara MedTech to Present at the Planet MicroCap Showcase: VEGAS 2025 on April 23, 2025April 10, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseChime’s Smart IPO: Half the Valuation, Double the StrengthBy Jeffrey Neal Johnson | June 18, 2025View Chime’s Smart IPO: Half the Valuation, Double the StrengthDarden Stock Set to Sizzle After Blowout Q4 and $1B BuybackBy Thomas Hughes | June 23, 2025View Darden Stock Set to Sizzle After Blowout Q4 and $1B BuybackSMTI, AORT, ESTA, and EYE Company DescriptionsArtivion NYSE:AORT$31.17 +0.55 (+1.79%) Closing price 06/27/2025 03:59 PM EasternExtended Trading$31.18 +0.01 (+0.04%) As of 06/27/2025 07:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.Establishment Labs NASDAQ:ESTA$40.93 +0.09 (+0.22%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$40.90 -0.03 (-0.07%) As of 06/27/2025 07:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander. The company sells its products to physicians, hospitals, and clinics through distributors and direct sales force in Europe, the Middle East, Latin America, and Asia. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.National Vision NASDAQ:EYE$23.17 +0.11 (+0.48%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$22.66 -0.51 (-2.18%) As of 06/27/2025 05:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.National Vision Holdings, Inc., through its subsidiaries, operates as an optical retailer in the United States. The company operates in two segments, Owned & Host and Legacy. It offers eyeglasses and contact lenses, and optical accessory products; provides eye exams through its America's Best, Eyeglass World, Vista Optical, Fred Meyer, and Vista Optical military, as well as Vision Center branded stores; and offers health maintenance organization and optometric services. National Vision Holdings, Inc. was founded in 1990 and is headquartered in Duluth, Georgia.Sanara MedTech NASDAQ:SMTI$28.41 +0.05 (+0.18%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$28.42 +0.01 (+0.04%) As of 06/27/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. It also provides BIAKOS Antimicrobial Skin and Wound Cleanser, a patented product that contains synergistic ingredients that have been shown to impact mature biofilm microbes; BIAKOS Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing that helps against planktonic microbes, as well as immature and mature biofilms; and BIAKOS Antimicrobial Skin and Wound Irrigation Solution. In addition, it develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement; and VIM Amnion Matrix, a homologous wound covering product. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Addition by Subtraction: Intel’s New Strategy Energizes Investors Apple: The Mag 7’s Dead Money Stock or AI Cash Cow in the Making? NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Rocket Lab: Europe Comes Calling as Momentum Builds Broadcom’s Big VMware Update: A Threat to Public Cloud Giants? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
